S
Sreevidya Kurra
Researcher at Stanford University
Publications - 6
Citations - 458
Sreevidya Kurra is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 1, co-authored 2 publications receiving 4 citations.
Papers
More filters
Journal ArticleDOI
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner,Sneha Ramakrishna,Kristen W. Yeom,Shabnum Patel,Harshini Chinnasamy,Liora M. Schultz,Rebecca Richards,Li Jiang,Valentin Barsan,Rebecca A Mancusi,Anna Geraghty,Zina Good,Aaron Mochizuki,Shawn M. Gillespie,Angus Toland,Jasia Mahdi,Agnes Reschke,Esther H Nie,Isabelle J. Chau,Maria Caterina Rotiroti,Christopher Mount,Christina Baggott,Sharon Mavroukakis,Emily Egeler,Jennifer Moon,Courtney Erickson,Sean Green,Michael Kunicki,Michelle Fujimoto,Zach Ehlinger,Warren D. Reynolds,Sreevidya Kurra,Katherine E. Warren,Snehit Prabhu,Hannes Vogel,Lindsey Rasmussen,Timothy T. Cornell,Sonia Partap,Paul B. Fisher,Cynthia J. Campen,Mariella G. Filbin,Gerald A. Grant,Bita Sahaf,Kara L. Davis,Steven R. Feldman,Crystal L. Mackall,Michelle Monje +46 more
TL;DR: In this paper , the clinical experience from the first four patients with H3K27M-mutated diffuse midline glioma (DIPG) or spinal cord DMG treated with GD2-CAR T cells at dose level 1 (1 × 106 GD2 CAR T cells per kg administered intravenously).
Journal ArticleDOI
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner,Sneha Ramakrishna,Kristen W. Yeom,Shabnum Patel,Harshini Chinnasamy,Liora M. Schultz,Rebecca Richards,Li Jiang,Valentin Barsan,Rebecca A Mancusi,Anna Geraghty,Zina Good,Aaron Mochizuki,Shawn M. Gillespie,Angus Toland,Jasia Mahdi,Agnes Reschke,Esther H Nie,Isabelle J. Chau,Maria Caterina Rotiroti,Christopher Mount,Christina Baggott,Sharon Mavroukakis,Emily Egeler,Jennifer Moon,Courtney Erickson,Sean Green,Michael Kunicki,Michelle Fujimoto,Zach Ehlinger,Warren D. Reynolds,Sreevidya Kurra,Katherine E. Warren,Snehit Prabhu,Hannes Vogel,Lindsey Rasmussen,Timothy T. Cornell,Sonia Partap,Paul B. Fisher,Cynthia J. Campen,Mariella G. Filbin,Gerald A. Grant,Bita Sahaf,Kara L. Davis,Steven A. Feldman,Crystal L. Mackall,Michelle Monje +46 more
TL;DR: In this paper , the clinical experience from the first four patients with H3K27M-mutated diffuse midline glioma (DIPG) or spinal cord DMG treated with GD2-CAR T cells at dose level 1 (1 × 106 GD2 CAR T cells per kg administered intravenously).
Journal ArticleDOI
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Zina Good,Jay Y. Spiegel,Bita Sahaf,Meena Malipatlolla,Zach Ehlinger,Sreevidya Kurra,Moksha Desai,Warren D. Reynolds,Anita Wong Lin,Panayiotis Vandris,Fang Wu,Snehit Prabhu,Mark P. Hamilton,John S. Tamaresis,Paul Hanson,Shabnum Patel,Steven R. Feldman,Matthew J. Frank,John H. Baird,Lori Muffly,Gursharan K. Claire,Juliana Craig,Katherine A. Kong,Dhananjay A. Wagh,John A. Coller,Sean C. Bendall,Robert Tibshirani,Sylvia K. Plevritis,David B. Miklos,Crystal L. Mackall +29 more
TL;DR: In this paper , a single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4+Helios+ CART cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity.
Proceedings ArticleDOI
Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner,Sneha Ramakrishna,Aaron Mochizuki,Shabnum Patel,Harshini Chinnasamy,Kristen W. Yeom,Liora M. Schultz,Rebecca Richards,Cynthia J. Campen,Agnes Reschke,Jasia Mahdi,Angus Toland,Christina Baggott,Sharon Mavroukakis,Emily Egeler,Jennifer Moon,Kayla Landrum,Courtney Erickson,Lindsey Rasmussen,Valentin Barsan,John S. Tamaresis,Anne Cunniffe Marcy,Michael Kunicki,Michelle Fujimoto,Zach Ehlinger,Sreevidya Kurra,Timothy T. Cornell,Sonia Partap,Paul G. Fisher,Gerald A. Grant,Hannes Vogel,Bita Sahaf,Kara L. Davis,Steven A. Feldman,Crystal L. Mackall,Michelle Monje +35 more
TL;DR: This is the first report of GD2 CAR T cell therapy for DIPG and spinal cord DMG and toxicities are similar to other CAR T cells with additional, manageable complications due to inflammation at CNS sites of tumor.
Journal ArticleDOI
Epct-14. gd2 car t-cells mediate clinical activity and manageable toxicity in children and young adults with h3k27m-mutated dipg and spinal cord dmg
Robbie G. Majzner,Sneha Ramakrishna,Aaron Mochizuki,Shabnum Patel,Harshini Chinnasamy,Kristen W. Yeom,Liora M. Schultz,Rebecca Richards,Cynthia J. Campen,Agnes Reschke,Jasia Mahdi,Angus Toland,Christina Baggott,Sharon Mavroukakis,Emily Egeler,Jennifer Moon,Kayla Landrum,Courtney Erickson,Lindsay Rasmussen,Valentin Barsan,John S. Tamaresis,Anne Cunniffe Marcy,Michael Kunicki,Michelle Fujimoto,Zach Ehlinger,Sreevidya Kurra,Timothy T. Cornell,Sonia Partap,Paul G. Fisher,Gerald A. Grant,Hannes Vogel,Bita Sahaf,Kara L. Davis,Steven A. Feldman,Crystal L. Mackall,Michelle Monje +35 more